巴曲酶联合低分子肝素治疗下肢深静脉血栓的临床疗效及安全性评价  

Batroxobin combined with low molecular heparin in the treatment of deep venous thrombosis in elderly patients

作　　者：王国华[1,2] 唐黎明[1,2] 马玉亮[1,2] 孙一峰[1,2] 黄洪亮[1,2] 徐妙军[1,2] 费晓舟[1,2] 

机构地区：[1]绍兴市人民医院 [2]浙江大学绍兴医院血管疝外科,浙江绍兴312000

出　　处：《中国临床药理学杂志》2015年第12期1103-1105,共3页The Chinese Journal of Clinical Pharmacology

基　　金：绍兴市科技基金资助项目(2014B70078)

摘　　要：目的评价巴曲酶联合低分子肝素治疗老年患者下肢深静脉血栓的临床疗效和安全性。方法将65例老年下肢深静脉血栓患者随机分为试验组32例和对照组33例。对照组予以低分子肝素5000 U皮下注射,bid;试验组在对照组基础上,加用巴曲酶5 BU静脉滴注,隔日1次(首剂10 BU),总量25 BU,2组疗程均为7 d。治疗后,比较2组患者的临床疗效、血液学指标及不良反应发生率有无差别。结果试验组与对照组总有效率分别为90.63%和84.85%,差异无统计学意义(P>0.05),但试验组显效率68.75%显著高于对照组33.33%(P<0.05)。试验组与对照组治疗后D-二聚体、纤维蛋白原较治疗前显著降低(P<0.05),凝血酶原时间显著延长(P<0.05),但治疗后组间上述指标差异无统计学意义(P>0.05)。2组患者轻微出血发生率分别为9.38%和6.06%(P>0.05)。结论巴曲酶联合低分子肝素治疗老年患者下肢深静脉血栓是安全、有效的。Objective To evaluate the clinical activity and safety of ba-troxobin combined with low molecular heparin in the treatment of deep venous thrombosis in elderly patients.Methods A total of 65 patients diagnosed with deep venous thrombosis were recruited in our hospital and randomly divided into control group （ n =33 ） and experiment group （ n=32 ） .Patients in the control group were given low molecular heparin 5000 U through hypodermical injection twice a day for 7 days.Patients in the experiment group were given batroxobin 5 BU qod（ first dosage of 10 BU, totaling 25 BU） plus low molecular heparin 5000 U hypodermical injection twice a day for 7 days.After treatment, the clinical efficacy, serum index and safety were compared between the two groups. Results The clinical efficacy were 90.63%and 84.85%in the experi-ment and control group respectively without statistical difference （P〉0.05）.But the excellence rate in experiment group was significant-ly higher than that in the control group （ P 〈0.05 ） .The D -dimer, fibrinogen were significantly decreased and prothrombin time was signifi-cantly prolonged in the both groups after treatment （ P 〈0.05 ） .The slight bleeding rate were 9.38% and 6.06% in the experiment and control group respectively without statistical difference （ P 〉0.05 ） .Conclusion Batroxobin combined with low molecular heparin in the treatment of deep venous thrombosis in elderly patients is effective and safe.

关 键 词：下肢深静脉血栓 巴曲酶 低分子肝素 临床疗效 安全性 

分 类 号：R973.2[医药卫生—药品] R364.17[医药卫生—药学]